Enzon Pharmaceuticals, Inc.
ENZN
$0.0998
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.41% | 0.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.41% | 0.00% | |||
| Operating Income | 7.41% | -8.00% | |||
| Income Before Tax | -27.06% | 8.21% | |||
| Income Tax Expenses | 497.96% | 1,125.00% | |||
| Earnings from Continuing Operations | -128.35% | -7.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -128.35% | -7.97% | |||
| EBIT | 7.41% | -8.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 189.19% | -8.82% | |||
| Normalized Basic EPS | -26.92% | 8.33% | |||
| EPS Diluted | 189.19% | -8.82% | |||
| Normalized Diluted EPS | -26.92% | 8.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||